Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.zyduscadila.com | |
Market Cap | 43,787.95 Cr. | |
Enterprise Value(EV) | 45,422.85 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 19.15 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 22.59 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.44 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 164.64 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.63 | Calculated using Price: 432.60 |
Dividend Yield | 0.58 | Period Ending 2022-03 |
No. of Shares Subscribed | 101.22 Cr. | 1,012,204,139 Shares |
FaceValue | 1 | |
Company Profile | ||
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses. |
1 Day |
|
-0.69% |
1 Week |
|
+1.53% |
1 Month |
|
+3.11% |
3 Month |
|
-0.92% |
6 Month |
|
+23.51% |
1 Year |
|
+4.37% |
2 Year |
|
-7.45% |
5 Year |
|
+5.64% |
10 Year |
|
+152.27% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 26.20 | 30.85 | 38.62 | 23.43 | 22.26 | 19.36 | 11.32 | 18.88 | 15.51 | |
Return on Capital Employed (%) | 17.67 | 23.21 | 28.60 | 16.50 | 18.41 | 15.89 | 10.02 | 14.23 | 15.30 | |
Return on Assets (%) | 10.89 | 13.93 | 20.14 | 12.18 | 11.11 | 9.34 | 5.18 | 9.66 | 9.40 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 3,439 | 4,252 | 5,699 | 6,960 | 8,745 | 10,386 | 10,376 | 12,992 | 17,000 | 16,665 | |
Non Curr. Liab. | 1,589 | 1,342 | 736 | 1,903 | 2,122 | 3,491 | 2,854 | 19 | -194 | -426 | |
Curr. Liab. | 2,814 | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,839 | 6,121 | |
Minority Int. | 144 | 169 | 136 | 156 | 191 | 1,293 | 1,335 | 1,937 | 2,054 | 2,103 | |
Equity & Liab. | 7,987 | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,463 | |
Non Curr. Assets | 4,549 | 4,820 | 5,752 | 8,303 | 8,911 | 14,015 | 14,118 | 14,094 | 14,438 | 14,751 | |
Curr. Assets | 3,438 | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,261 | 9,712 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 7,987 | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,463 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 7,224 | 8,651 | 9,427 | 9,377 | 11,955 | 13,166 | 14,253 | 14,404 | 15,265 | 15,726 | |
Other Income | 86 | 57 | 117 | 147 | 133 | 209 | 117 | 47 | 235 | 250 | |
Total Income | 7,310 | 8,709 | 9,543 | 9,524 | 12,088 | 13,374 | 14,370 | 14,451 | 15,501 | 15,976 | |
Total Expenditure | -6,031 | -6,897 | -7,097 | -7,475 | -9,126 | -10,187 | -11,473 | -11,018 | -11,935 | -12,608 | |
PBIDT | 1,279 | 1,811 | 2,446 | 2,049 | 2,962 | 3,187 | 2,897 | 3,433 | 3,565 | 3,369 | |
Interest | -118 | -68 | -53 | -63 | -111 | -196 | -342 | -159 | -127 | -139 | |
Depreciation | -201 | -287 | -292 | -373 | -539 | -599 | -697 | -670 | -713 | -731 | |
Taxation | -106 | -259 | -177 | -129 | -564 | -530 | -320 | -194 | -512 | -475 | |
Exceptional Items | -17 | -10 | -3 | 0 | -10 | -364 | -205 | 113 | -3 | ||
PAT | 836 | 1,186 | 1,921 | 1,483 | 1,748 | 1,852 | 1,176 | 2,206 | 2,326 | 2,020 | |
Minority Interest | -33 | -38 | -30 | -29 | -35 | -50 | -28 | -51 | -131 | -128 | |
Share Associate | 43 | 34 | 63 | 47 | 29 | 47 | 46 | 64 | |||
Other Related Items | |||||||||||
Consolidated Net Profit | 804 | 1,151 | 1,934 | 1,488 | 1,776 | 1,849 | 1,177 | 2,134 | 4,487 | 1,939 | |
Adjusted EPS | 8 | 11 | 19 | 15 | 17 | 18 | 11 | 21 | 44 | 19 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 603 | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | |
Cash Fr. Inv. | -682 | -438 | -465 | -864 | -2,872 | -974 | -4,239 | -1,012 | -725 | 1,154 | |
Cash Fr. Finan. | 286 | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | |
Net Change | 207 | -64 | 178 | 95 | 756 | -3 | -1,072 | 391 | 22 | 2,390 | |
Cash & Cash Eqvt | 677 | 613 | 790 | 837 | 1,593 | 1,590 | 779 | 1,178 | 1,087 | 3,460 |
Mon, 30 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Q3 FY23 post results earning call details |
Fri, 27 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release We wish to inform that the USFDA conducted an inspection at the manufacturing facility of Zydus Lifesciences Limited located at Moraiya Ahmedabad from 23rd to 27th January 2023. Theinspection was a Pre-Approval Inspection (PAI) for Transdermal Patch products. The inspection concluded with NIL observations. |
Mon, 23 Jan 2023
Board Meeting Intimation for Approval Of Unaudited Financial Results Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve unaudited financial results for the quarter / nine months ended on December 31 2022. |
Thu, 02 Feb 2023 |
|
|
|
Wed, 01 Feb 2023 |
|
|